NEW on the #AJKDBlog: @maximalchange.bsky.social interviews Niraj B. Desai, Casey Gashti, and @nephrowhitt.bsky.social about the history of lupus nephritis and several exciting new therapies:

Lupus Nephritis, “A Change Is Gonna Come”: An Interview

Systemic lupus erythematosus (SLE) is a chronic, multiorgan autoimmune disease, with lupus nephritis (LN) affecting up to 60% of patients. Early diagnosis and treatment are critical for preserving …

bit.ly

8/10 #NephJC Consensus 1️⃣BI 764198 administration in 1° FSGS caused a modest ⬇️UPCR 2️⃣Unclear if this will lead to better eGFR outcomes in a heterogenous group of FSGS pts 3️⃣Appears most helpful in genetic FSGS with TRPC6 mutations

5/10 A figure paints🖼️ a 1000 words! This figure is… a lot. Full analysis & per protocol sets at various doses Small # in each group A) 1° endpoint: 25% ⬇️ UPCR from baseline D) Proportion achieving a UPCR of <1 g/g E) Δ in 24 h UPCR in pts with confirmed TRPC6

4/10 One post results Of the 60 pts: 1° endpoint (≥ 25% ⬇️ in UPCR from baseline at week 12) was seen in 7% of placebo vs 35% of all BI 764198 dose groups OR 4.9 [95% CI 1.0–48.8]

3/10 One post methods Phase 2, multicentric/multinational, parallel-group, placebo controlled RCT Primary FSGS or genetic FSGS resulting from a TRPC6 variant. Patients were given 20/40/80 mg of study drug

N-propargylglycine restores survival by preventing calcium oxalate stone formation, tubular injury, and kidney dysfunction in a lethal mouse model of primary hyperoxaluria type 2 doi.org/10.1016/j.kint.2026.02.024 #MedSky #NephSky #OpenAccess

📢 The FDA has approved the first ever treatment for FSGS, supported by the PARASOL initiative. RaDaR contributed as an external validation cohort, highlighting the power of global collaboration & patient data. 📰: https://ow.ly/IJNH50YJXBB #RareDisease #KidneyResearch #FSGS

#NephMadness 2026 Really enjoyed this year’s writeups.. thoughtful and high-yield 👏 There’s a clear shift in nephrology: from broad immunosuppression → more targeted therapies. Still learning the ropes, but this was fun 🙂 Curious to see which direction the panel leans 👀 #NephMadnessNewbie

#NephMadness 2026: The PodCrawl Featuring these podcasts: - GN in Ten @isgd.bsky.social - Global Kidney Care @theisn.org - @freelyfiltered.bsky.social - @febrilepodcast.com - Kidney Commute @nkf-professionals.bsky.social - @coreimpodcast.bsky.social - Nephron Segment bit.ly/NM26Podcrawl

#NephMadness 2026: The PodCrawl

Submit your picks! |  @NephMadness |@nephmadness.bsky.social | NephMadness 2026 Do you prefer your information in audio form?  If so, bookmark this page, where we’ll be sharing links to NephM…

bit.ly

⏰ Just a few hours left to submit your #NephMadness 2026 bracket! The fun of #NephMadness is making your prediction on which team will become the 2026 Champion. Already submitted one? Disagreed with the group? Submit a back-up bracket: bit.ly/2DvWyou

Also see this study from India in @kireports.bsky.social Is there somethung special about targeted release $$$ vs enteric coated $ budesonide? bsky.app/profile/hswa... #ISNWCN

Swapnil Hiremath 🍁🇨🇦@hswapnil.medsky.social · 5mo ago

Very cool Enteric coated budesonide also reduces albuminuria, and GFR remains stable in #IgAN Single arm prospective study from India in KI Reports www.kireports.org/article/S246...

Hi, I’m Sruthi, Nephrologist from Kerala, India. I’m into clinical medicine, research, and lately curious about AI. Outside work, I enjoy time with family, art, and real conversations. Here to learn, connect, and grow 🙂 #Nephsky #Nephbluesky #Medsky